RARA CRAFT DATABASE for FDA Medical Devices
510(k)K192326

FDA DEVICE FACTS

HardyDisk AST Lefamulin 20µg (LMU20)

Hardy Diagnostics

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATESeptember 19, 2019PRODUCT CODEJTN

Indications for use

HardyDisk AST Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens. Standardized methods for agar diffusion testing have been described for Enterobacteriaceae, Staphylococcus spp., Pseudomonas spp., Acinetobacter spp., Listeria monocytogenes, Enterococcus spp., and by modified procedures, Haemophilus spp., Neisseria gonorrhoeae, N. meningitidis and Streptococcus spp., including Streptococcus pneumoniae. Use of HardyDisk AST Lefamulin 20µg (LMU20) for in vitro agar diffusion susceptibility testing is indicated when there is the need to determine the susceptibility of bacteria to Lefamulin. HardyDisk AST Lefamulin at concentration 20µg can be used to determine the zone diameter (mm) of Lefamulin against the following bacteria for which Lefamulin has been shown to be active both clinically and in vitro: Streptococcus pneumoniae Staphylococcus aureus (methicillin-susceptible isolates) Haemophilus influenzae

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 25, 2026